Cannabinoid‐induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats
@article{Braida2000CannabinoidinducedWM, title={Cannabinoid‐induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats}, author={Daniela Braida and Mariaelvina Sala}, journal={NeuroReport}, year={2000}, volume={11}, pages={2025–2029} }
Cannabinoids which impair rat working memory appear to inhibit hippocampal extracellular acetylcholine (Ach) release and reduce choline uptake through an interaction with CB1 cannabinoid receptors. Here we report that CP 55,940, a potent bicyclic synthetic cannabinoid analog, dose–dependently impaired rat performance, when given i.p. 20 min before an eight-arm radial maze test. The selective CB1 cannabinoid receptor antagonist SR 141716A, given i.p. 20 min earlier, significantly reduced the…
55 Citations
Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.
- Biology, PsychologyLearning & memory
- 2010
The notion that cannabinoid-modulated cholinergic activity is a mechanism underlying the performance deficits in DNMS is supported, whether deficits are due to reduced nicotinic or muscarinic receptor activation, or both, awaits further analysis.
Cannabinoids alter recognition memory in rats.
- Biology, PsychologyPolish journal of pharmacology
- 2003
First evidence that cannabinoids impair recognition memory in rats is found, as a stable analogue of endogenous cannabinoid anandamide and a potent CB(1) receptor agonist, CP 55,940 significantly attenuated recognition memory.
WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction
- Biology, PsychologyBehavioural Brain Research
- 2010
Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats
- Biology, PsychologyPsychopharmacology
- 2007
Systemic Rimonabant-induced deficits are due to anxiogenic properties of the drug and the possibility that selective inactivation of hippocampal CB1 receptors may be memory enhancing is discussed.
How do stupendous cannabinoids modulate memory processing via affecting neurotransmitter systems?
- Biology, PsychologyNeuroscience & Biobehavioral Reviews
- 2021
Cannabinoids and prefrontal cortical function: Insights from preclinical studies
- Biology, PsychologyNeuroscience & Biobehavioral Reviews
- 2006
The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study.
- Biology, MedicineCerebral cortex
- 2001
In vivo and in vitro findings suggest an increase in cortical glutamatergic transmission by CB(1) receptors, an effect that may underlie some of the psychoactive and behavioural actions of acute exposure to marijuana.
Cellular Mechanisms Underlying the Anxiolytic Effect of Low Doses of Peripheral Δ9-Tetrahydrocannabinol in Rats
- Biology, PsychologyNeuropsychopharmacology
- 2007
The results suggest that the stimulation of CB1 receptors in the prefrontal cortex, amygdala, and hippocampus with the subsequent activation of different signaling pathways is the first event underlying the effects of cannabinoids on anxious states.
Endocannabinoids in cognition and dependence.
- Biology, PsychologyProstaglandins, leukotrienes, and essential fatty acids
- 2002
Converging evidence in which performance in a variety of memory tasks is enhanced following either SR141716A treatment or in CB(1) receptor knockout mice indicates that this system may play an important role in modulating cognition.
5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats.
- Biology, ChemistryEuropean journal of pharmacology
- 2007
References
SHOWING 1-10 OF 10 REFERENCES
Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.
- BiologyThe Journal of pharmacology and experimental therapeutics
- 1996
The results suggest that cannabinoid receptor activation can produce a strong inhibition of ACh release in the hippocampus, and suggests that this compound is an inverse agonist at cannabinoid receptors or it is antagonizing the actions of an endogenous ligand acting on these receptors.
Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat.
- Biology, PsychologyEuropean journal of pharmacology
- 1991
Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells.
- Biology, PsychologyThe Journal of pharmacology and experimental therapeutics
- 1993
Findings strongly suggest that performance of the DMTS task was selectively impaired by the lack of Sample phase discharge of hippocampal neurons during theDMTS trial, and that this effect could serve as the basis for the well characterized short-term memory and other cognitive deficits reported in humans after smoking marijuana.
Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A.
- Biology, ChemistryEuropean journal of pharmacology
- 1997
Dimen KR and Martin BR
- Psychopharmacology 119,
- 1995
Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study
- Biology, MedicineBrain Research
- 1993
Effects of delta 9-tetrahydrocannabinol and cannabidiol on sodium-dependent high affinity choline uptake in the rat hippocampus.
- Biology, ChemistryThe Journal of pharmacology and experimental therapeutics
- 1980
The results suggest that the septal-hippocampal cholinergic tract is a major site of action of delta 9-THC and may provide a neurochemical basis for the differential pharmacological properties of delta 8-Tetrahydrocannabinol and CBD.
Handbook of Experimental Pharmacology: Pharmacological Aspects of Drug Dependence
- 1996
Acknowledgements: This study was supported by grant from Ministero della Ricerca Scienti®ca e Tecnologica
- Pharmacol Biochem Behav 32,
- 1989